@article {2229, title = {New Insights of Oxidative Stress and Thalassemia May Lead to Antioxidant Therapy}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {February 2024}, pages = {202-204}, type = {Research Article}, chapter = {202}, abstract = {

Background: Because of chronic hemolysis, thalassemic patients are under oxidative cell injury caused by secondary iron overload. This provokes oxidative damage to the cellular membranes of organs that accumulate excess iron. Several researchers studied the oxidative stress in patients with thalassemia during chelation therapy and repeated blood transfusion periods, and they found that β-thalassemia patients are under oxidative stress, but they did not focus on before the chelating therapy period. Objective: To evaluate the total antioxidant capacity (TAOC) and oxidative stress (OS) in newly diagnosed patients with β-thalassemia before chelating therapy. Methodology: In the present case-control study, twenty patients newly diagnosed with β-thalassemia before receiving chelating agents, and another 30 healthy individuals, sex-matched with patients, considered as a control, were included in the study. Total antioxidant capacity (TAOC) and Malondialdehyde (MDA) were assessed in the studied groups. Results: The TAOC values of the thalassemic group (35{\textpm}0.11 u/ml ) were significantly (p\<0.001) lower than that of the control group (79{\textpm}7.2 u/ml). MDA values of the thalassemic group (7.9 {\textpm}2.35nmol/l) were significantly (p\<0.001) more than that of the control group (0.57{\textpm}0.25 nmol/l). Conclusion: The present study demonstrated that patients with β thalassemia have decreased values of TAOC, and increased values of MDA when compared with the control group.

}, keywords = {Antioxidants, Oxidative stress, Thalassemia}, doi = {10.5530/pj.2024.16.28}, author = {Kassim SA Al Neaimy and Maes MK Alkhyatt and Israa A Jarjess} } @article {1853, title = {Thalassemia β Major in Confirmed Covid-19 Patient: A Case Report}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {August 2022}, pages = {445-449}, type = {Case Report}, chapter = {445}, abstract = {

The incidence of Thalassemia with confirmed Covid 19 is very rare. The aim of this study is to know the prognosis and evaluate the management of therapy in thalassemia β Mayor patients with COVID-19. This case study describes the progression of Thalassemia β Mayor with COVID 19 starting from how to establish the diagnosis of Thalassemia β Mayor and COVID 19 until how to treat thalassemia β Mayor patients with COVID-19 This case study result describes that COVID 19 aggravates thalassemia β Mayor. Infection can adversely affect thalassemia. Giving Blood transfusions must be done due to anemia in Thalassemia, but it will have an impact on the accumulation of iron in the body which will increase the severity of the infection. The administration of iron-chelation drugs is beneficial for Covid but on the other hand, it is contraindicated in Thalassemia patients.

}, keywords = {COVID-19, Infection, Preventable Death, Thalassemia}, doi = {10.5530/pj.2022.14.119}, author = {Yosua Butar Butar and Puspa Wardhani} }